Qitan technology has raised more than 400 million yuan in round B financing, and is jointly led by hillhood venture capital and CDH VGC
Summary
According to the news of yiou health on June 8, Qitan technology officially announced today that it has completed more than 400 million RMB round B financing, which is jointly led by Hillhead venture capital and CDH VGC (innovation and Growth Fund), followed by Boyuan capital, Huagai capital and sunshine Ronghui capital, and continued to increase the weight of old shareholders Gaorong capital, Zhongguancun collaborative innovation fund, ginkgo Valley capital and Yahui investment. Qicarbon technology focuses on the independent R & D, manufacturing and application development of nanopore single molecule gene sequencer and supporting reagents and chips. Its first domestic self-developed nanopore gene sequencer is planned to be mass produced within this year. At that time, Qitan technology will become the only domestic company of the fourth generation of gene sequencing technology, and the second enterprise in the world to enter the commercial application stage. The situation of foreign monopoly on the core technology of gene sequencing will be broken.